JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

An exploratory SWATH plasma proteomics analysis of phyllodes tumor- a type of female breast tumor

  • 0CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences +

|

February 11, 2025

|

February 11, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

This study identified 30 altered plasma proteins in phyllodes tumors (PT) using SWATH-LC-MS proteomics. These findings may lead to new diagnostic markers and therapeutic targets for this rare breast cancer.

Area Of Science

  • Oncology
  • Proteomics
  • Biomarker Discovery

Background

  • Phyllodes tumors (PT) are rare fibroepithelial breast neoplasms with unclear molecular underpinnings.
  • Identifying reliable plasma biomarkers for PT is crucial for diagnosis and treatment.

Purpose Of The Study

  • To discover potential plasma biomarkers for phyllodes tumors.
  • To compare the plasma proteome of PT cases with healthy controls using a mass spectrometry-based approach.

Main Methods

  • Plasma samples from PT cases and controls were analyzed using Sequential Window Acquisition of All Theoretical Fragment Ion Spectra-Liquid Chromatography-Mass Spectrometry/Mass Spectrometry (SWATH-LC-MS/MS).
  • Proteins with a fold change of ≥1.5 and p-value <0.05 were considered significant.
  • Protein-protein interaction network analysis was performed using STRING database.

Main Results

  • 319 proteins were identified, with 30 significantly altered (26 upregulated, 4 downregulated) in PT cases compared to controls.
  • Protein-protein network analysis highlighted 19 highly connected proteins involved in biological pathways.
  • Specific proteins (e.g., APMAP, HGFAC, TTR, PNO3) and pathways (e.g., FCGR3A-mediated IL10 synthesis, Wnt/β-catenin) were significantly altered.

Conclusions

  • This is the first exploratory SWATH-LC-MS/MS proteomics study on phyllodes tumors.
  • The identified altered proteins and pathways offer potential theranostic markers and druggable targets for PT.
  • Further research is warranted to validate these findings for clinical application.